Sino Biopharm 1177

Re: Sino Biopharm 1177

Postby winston » Tue Feb 23, 2021 1:08 pm


BofAS Lifts SINO BIOPHARM TP to $14.73, Yet to Reflect Sinovac’s Vaccine Contribution

BofA Securities restated SINO BIOPHARM (01177.HK) at Buy, raising its target from $9.79 to $14.73.

Valuation of China's big healthcare firms hit record-highs, rendering investors more prudent on drugmakers.

SINO BIOPHARM is the broker's high conviction pick compared with other leaders, given understated profit contribution from Sinovac and underestimated vaccine assets.

SINO BIOPHARM's valuation has yet to factor in profit contribution from Sinovac.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
Billionaire Boss
Posts: 110553
Joined: Wed May 07, 2008 9:28 am


Return to S to Z

Who is online

Users browsing this forum: No registered users and 3 guests